Restatement of Previously Issued Financial Statements - Schedule of Restatement of Statement of Operations (Details) - USD ($) |
3 Months Ended | 9 Months Ended | 12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 |
Jun. 30, 2022 |
Mar. 31, 2022 |
Sep. 30, 2021 |
Jun. 30, 2021 |
Mar. 31, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
Dec. 31, 2021 |
Dec. 31, 2020 |
|
| Ratchet share expense | $ 1,099,360 | $ 1,099,360 | ||||||||
| Loss from operations | (5,095,586) | $ (2,233,247) | (11,981,188) | $ (4,787,216) | $ (7,786,627) | $ (6,975,601) | ||||
| Change in fair value of warrant liability | 128,030 | (100,780) | 128,030 | (1,546,280) | (1,546,280) | (19,600) | ||||
| Other income (expense) net | 191,773 | (2,970,321) | 357,647 | (4,898,261) | (4,791,584) | 16,353 | ||||
| Net loss | (4,903,813) | $ (3,305,883) | $ (3,413,845) | (5,203,568) | $ (2,956,324) | $ (1,525,585) | (11,623,541) | (9,685,477) | (12,578,211) | (6,959,248) |
| Net loss attributable to MAIA Biotechnology, Inc. shareholders | $ (4,903,813) | $ (5,196,438) | $ (12,074,119) | $ (9,611,146) | $ (12,503,880) | $ (6,636,660) | ||||
| Net loss per share basic | $ (0.48) | $ (1.02) | $ (1.39) | $ (2.06) | $ (2.37) | $ (1.50) | ||||
| Net loss per share diluted | $ (0.48) | $ (1.02) | $ (1.39) | $ (2.06) | $ (2.37) | $ (1.50) | ||||
| As Previously Reported | ||||||||||
| Loss from operations | $ (3,996,226) | $ (10,881,828) | ||||||||
| Other income (expense) net | 63,743 | 229,617 | ||||||||
| Net loss | (3,932,483) | (10,652,211) | ||||||||
| Deemed dividend on ratchet shares | (1,099,360) | (1,099,360) | ||||||||
| Net loss attributable to MAIA Biotechnology, Inc. shareholders | $ (5,031,843) | $ (12,202,149) | ||||||||
| Net loss per share basic | $ (0.49) | $ (1.40) | ||||||||
| Net loss per share diluted | $ (0.49) | $ (1.40) | ||||||||
| Adjustment | ||||||||||
| Ratchet share expense | $ 1,099,360 | $ 1,099,360 | ||||||||
| Loss from operations | (1,099,360) | (1,099,360) | ||||||||
| Change in fair value of warrant liability | 128,030 | 128,030 | ||||||||
| Other income (expense) net | 128,030 | 128,030 | ||||||||
| Net loss | (971,330) | (971,330) | ||||||||
| Deemed dividend on ratchet shares | 1,099,360 | 1,099,360 | ||||||||
| Net loss attributable to MAIA Biotechnology, Inc. shareholders | $ 128,030 | $ 128,030 | ||||||||
| Net loss per share basic | $ 0.01 | $ 0.01 | ||||||||
| Net loss per share diluted | $ 0.01 | $ 0.01 | ||||||||
| X | ||||||||||
- Definition Deemed dividend on ratchet shares. No definition available.
|
| X | ||||||||||
- Definition Ratchet share expense. No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. No definition available.
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|